Accucaps establishes SPC for high potency compounds

Accucaps said that the increase in growth of liquid filled soft gel formulated compounds is due to the increasing need to formulate high potency molecules that could not otherwise be provided in oral dose formulation.

Accucaps president Bruno Biscaro said that the expanded capability would allow Accucaps to address the needs of their customers in the formulation and commercialisation of specialised compounds which would ultimately improve patient outcomes.

Accucaps Sales and Marketing VP Sylvain Desjeans said that they have already begun development on a number of these specialised compounds.